A phase 2 study of the oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor, rivoceranib, for recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC).

被引：0
|
作者：
Kang, Hyunseok
Ahn, Myung-Ju
Muzaffar, Jameel
Keam, Bhumsuk
Bowles, Daniel W.
Wong, Deborah J. L.
Ho, Alan Loh
Kim, Sung-Bae
Worden, Francis P.
Yun, Tak
Sari, Suha
Conlan, Maureen G.
Hanna, Glenn J.
机构：
[1] UCSF Helen Diller Family Comprehens Canc Ctr, Hematol Oncol, San Francisco, CA USA
[2] Sungkyunkwan Univ Sch Med, Samsung Med Ctr, Seoul, South Korea
[3] H Lee Moffitt Canc Ctr & Res Inst, Head & Neck & Endocrine Oncol, Tampa, FL USA
[4] Seoul Natl Univ Hosp, Seoul, South Korea
[5] Univ Colorado Canc Ctr, Div Med Oncol, Aurora, CO USA
[6] Univ Calif Los Angeles, Los Angeles, CA USA
[7] Mem Sloan Kettering Canc Ctr, Head & Neck Serv, Div Solid Tumor Oncol, New York, NY USA
[8] Univ Ulsan Coll Med, Asan Med Ctr, Seoul, South Korea
[9] Univ Michigan, Rogel Canc Ctr, Endocrine Oncol Clin, Ann Arbor, MI USA
[10] Natl Canc Ctr, Ctr Specif Organs Canc, Rare Cancers Clin, Goyang Si, Gyeonggi Do, South Korea
[11] Elevar Therapeut, Salt Lake City, UT USA
[12] Dana Farber Canc Inst, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6020
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Relationship between retention of a vascular endothelial growth factor receptor 2 (VEGFR2)-targeted ultrasonographic contrast agent and the level of VEGFR2 expression in an in vivo breast cancer model
    Lee, Debbie J.
    Lyshchik, Andrej
    Huamani, Jessica
    Hallahan, Dennis E.
    Fleischer, Arthur C.
    JOURNAL OF ULTRASOUND IN MEDICINE, 2008, 27 (06) : 855 - 866
  • [32] ZD6474, a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor, inhibits growth of multiple primary central nervous system tumor types
    Rich, JN
    Loncar, D
    Sathornsumetee, S
    Keir, S
    Wheeler, C
    Dimery, I
    Bigner, DD
    Friedman, HS
    NEURO-ONCOLOGY, 2004, 6 (04) : 413 - 413
  • [33] A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
    Mahmood, Umair
    Bang, Andrew
    Chen, Yu-Hui
    Mak, Raymond H.
    Lorch, Jochen H.
    Hanna, Glenn J.
    Nishino, Mizuki
    Manuszak, Claire
    Thrash, Emily M.
    Severgnini, Mariano
    Sanborn, Matthew
    Sridharan, Vishwajith
    Margalit, Danielle N.
    Tishler, Roy B.
    Busse, Paul M.
    Willers, Henning
    Mamon, Harvey J.
    Yoo, Hyung-Jin
    Pai, Sara, I
    Wirth, Lori J.
    Haddad, Robert, I
    Chau, Nicole G.
    Schoenfeld, Jonathan D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 109 (01): : 134 - 144
  • [34] A phase II trial cohort of nivolumab plus ipilimumab in patients (Pts) with recurrent/metastatic adenoid cystic carcinoma (R/M ACC).
    Tchekmedyian, Vatche
    Sherman, Eric Jeffrey
    Dunn, Lara
    Fetten, James Vincent
    Michel, Loren S.
    Kriplani, Anuja
    Morris, Luc
    Ostrovnaya, Irina
    Katabi, Nora
    Haque, Sofia
    Tran, Crystal
    Azar, Julian
    Pfister, David G.
    Ho, Alan Loh
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [35] Endorepellin, the Angiostatic Module of Perlecan, Interacts with Both the α2β1 Integrin and Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) A DUAL RECEPTOR ANTAGONISM
    Goyal, Atul
    Pal, Nutan
    Concannon, Matthew
    Paul, Matthew
    Doran, Mike
    Poluzzi, Chiara
    Sekiguchi, Kiyotoshi
    Whitelock, John M.
    Neill, Thomas
    Iozzo, Renato V.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (29) : 25947 - 25962
  • [36] LIVER VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR2 (VEGFR2) EXPRESSION IS UNRELATED TO HEPATITIS C (HCV) INFECTION IN HEPATOCELLULAR CARCINOMA (HCC)/CIRRHOSIS
    Aucejo, Federico
    Zein, Nizar
    Urso, Teresa Diago
    Quintini, Cristiano
    Hashimoto, Koji
    Eghtesad, Bijan
    Fung, John
    Miller, Charles
    Yerian, Lisa
    LIVER TRANSPLANTATION, 2008, 14 (07) : S124 - S124
  • [37] Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Contributes to Tamoxifen Resistance in Estrogen-Positive Breast Cancer Patients
    T. A. Dronova
    N. N. Babyshkina
    M. V. Zavyalova
    E. M. Slonimskaya
    N. V. Cherdyntseva
    Molecular Biology, 2021, 55 : 102 - 108
  • [38] Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Contributes to Tamoxifen Resistance in Estrogen-Positive Breast Cancer Patients
    Dronova, T. A.
    Babyshkina, N. N.
    Zavyalova, M. V.
    Slonimskaya, E. M.
    Cherdyntseva, N. V.
    MOLECULAR BIOLOGY, 2021, 55 (01) : 102 - 108
  • [39] The expression of vascular endothelial growth factor (VEGF)/endostatin (ES) and VEGF receptor 2 (VEGFR2)/ES is associated with NSCLC prognosis
    Yuan Yang
    Baohua Lu
    Baolan Li
    Weiying Li
    Mei Jiang
    Wentao Yue
    Qunhui Wang
    Tongmei Zhang
    Oncology and Translational Medicine, 2021, 7 (04) : 149 - 154
  • [40] Bronchial washing levels of vascular endothelial growth factor receptor-2 (VEGFR2) correlate with overall survival in NSCLC patients
    Charpidou, Andriani
    Gkiozos, Ioannis
    Konstantinou, Marios
    Eleftheraki, Anastasia
    Demertzis, Panagiotis
    Harrington, Kevin
    Polyzos, Aris
    Syrigos, Kostas N.
    CANCER LETTERS, 2011, 304 (02) : 144 - 153
12345